A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (NCT07005128)
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
🩺 Plain-English Summary (8th-Grade Level)
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (10 items).
Location: Cancer and Blood Specialists of Arizona — Casa Grande, Arizona
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Participants can have no history of other malignancy in the last 2 years.
- Any symptomatic central nervous system (CNS) metastases, or leptomeningeal disease.
- They will have no history of severe or life-threatening events to immune-mediated therapy.
- History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.
- They will have no active autoimmune or inflammatory disorders.
- Presence of active human immunodeficiency virus (HIV) or active Hepatitis (B/C) infection.
- Evidence or interstitial lung disease (ILD) or active, non-infectious pneumonitis.
- History of solid organ transplant.
- They will not have had a myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months prior to first dose of study treatment.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (164 Sites)
Showing the first 25 of 164 sites.
- Cancer and Blood Specialists of Arizona — Casa Grande, Arizona
- City of Hope Cancer Center Phoenix — Goodyear, Arizona
- Genesis Cancer Center — Hot Springs, Arkansas
- Saint Bernards Medical Center — Jonesboro, Arkansas
- Providence Saint Jude Medical Center — Fullerton, California
- Translational Research in Oncology US Inc, Trio Central Pharmacy — Los Angeles, California
- University of California Los Angeles — Santa Monica, California
- Presbyterian Intercommunity Hospital Health Whitter Hospital — Whittier, California
- Colorado West Healthcare System dba Grand Valley Oncology — Grand Junction, Colorado
- Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut — New Britain, Connecticut
- Yale New Haven Hospital — New Haven, Connecticut
- Eastern Connecticut Hematology and Oncology Associates — Norwich, Connecticut
- Florida Oncology and Hematology — Fort Myers, Florida
- Cancer Specialists of North Florida - Southpoint — Jacksonville, Florida
- Orlando Health Cancer Institute — Kissimmee, Florida
- Central Georgia Cancer Care PC — Macon, Georgia
- City of Hope Atlanta — Newnan, Georgia
- University of Illinois Chicago — Chicago, Illinois
- Cancer Care Specialists of Illinois — Decatur, Illinois
- Midwestern Regional Medical Center dba City of Hope Chicago — Rockford, Illinois
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Hematology Oncology of Indiana — Indianapolis, Indiana
- Cancer Center of Kansas, Heritage Plaza Medical Building — Wichita, Kansas
- New England Cancer Specialists — Westbrook, Maine
- Dana Farber Cancer Institute — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small-cell Lung Cancer
- A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer — Marietta, Georgia
- 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI) — Columbia, Missouri
- Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) — St Louis, Missouri
- Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer — Baltimore, Maryland
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer — Denver, Colorado
Explore by condition: All Small-cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.